WILMINGTON, Mass., Nov. 3/PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc. announces that its corporate highlights and third quarter financial results press release will be issued on Friday, November 6 at 6:30 a.m. to be followed by a conference call at 8:30 a.m.
Friday, November 6 - 8:30 a.m. E.T.
If calling from the US or Canada use the following toll-free number:
800.647.4314
Password - DUSA
For International callers use
502.498.8422
A recorded replay of the call will be available approximately 15 minutes
following the call
North American callers 877.863.0350
International callers 858.244.1268
The call will be accessible on our web site approximately six hours following the call at www.dusapharma.com.
About DUSA Pharmaceuticals
DUSA Pharmaceuticals, Inc.((R) )is an integrated dermatology pharmaceutical company focused primarily on the development and marketing of its Levulan((R)) Photodynamic Therapy technology platform, and complementary dermatology products. Levulan( )PDT is currently approved for the treatment of Grade 1 and 2 actinic keratoses of the face and scalp. DUSA also markets other dermatology products, including ClindaReach((R)). DUSA is researching Levulan PDT for the treatment of AKs and the prevention of new non-melanoma skin cancer in chronically immunosuppressed solid organ transplant recipients. DUSA is based in Wilmington, Mass. Please visit our web site at www.dusapharma.com.
DUSA Pharmaceuticals, Inc.
